✦ LIBER ✦

Acute myeloid leukemia developing during imatinib mesylate therapy for chronic myeloid leukemia in the absence of new cytogenetic abnormalities

✍ Scribed by Attaphol Pawarode; Sheila N.J. Sait; Alain Nganga; Lionel J. Coignet; Maurice Barcos; Maria R. Baer

Publisher: Elsevier Science
Year: 2007
Tongue: English
Weight: 171 KB
Volume: 31
Category: Article
ISSN: 0145-2126
DOI: 10.1016/j.leukres.2007.01.022

No coin nor oath required. For personal study only.

✦ Synopsis

The BCR/ABL tyrosine kinase inhibitor imatinib mesylate produces a high rate of cytogenetic responses in patients with Philadelphia (Ph)-positive chronic myeloid leukemia (CML), but secondary clonal chromosome abnormalities may develop in Ph-negative cells, and acute myeloid leukemia (AML) has been reported in patients with secondary chromosome abnormalities. We report a patient who developed AML during imatinib treatment of Ph-positive CML despite a cytogenetic response and absence of secondary chromosome abnormalities. Thus, development of AML as a rare event in CML patients with cytogenetic responses to imatinib therapy does not depend on the development of secondary cytogenetic abnormalities.

📜 SIMILAR VOLUMES

Philadelphia-negative acute myeloid leuk

Philadelphia-negative acute myeloid leukemia with new chromosomal abnormalities developing after first-line imatinib treatment for chronic phase chronic myeloid leukemia

✍ Carmen Fava; Jorge Cortes 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 306 KB 👁 2 views

## Induction of integrin b 1 expression in bone marrow cells after chemotherapy correlates with the overexpression of lung resistance protein and poor outcome in patients with multiple myeloma To the Editor: Acquired drug resistance continues to be one of the major obstacles hindering the successf

Development of acute myeloid leukemia as

Development of acute myeloid leukemia associated with Ph-negative clone with inv(3)(q21q26) during imatinib therapy for chronic myeloid leukemia

✍ Pavel Dvorak; Martina Hruba; Ivan Subrt 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 288 KB

P107 Chromosomal abnormalities in Philad

P107 Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome positive chronic myeloid leukemia in chronic phase

✍ S. Jootar 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 51 KB

6/155), high white cell number (13/155) (red cell unit) or low thrombocyte number (14/125) (thrombocyte unit). Summary: Donors with low hemoglobin levels have to be excluded from the blood donation service for 3 months. So, in theory haemoglobin concentration of all total blood units is suitable for

Is it possible to discontinue imatinib m

Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature

✍ Salvatore Guastafierro; Umberto Falcone; Maria Celentano; Milena Coppola; Maria 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 111 KB

Imatinib mesylate (IM) therapy leads to a complete cytogenetic response (CCyR) in 75-90% of Chronic Myeloid Leukemia (CML) patients in chronic phase, but only a small percentage of patients achieve complete molecular response (CMR). Very little is known about IM discontinuation. We report the case o

No significance of derivative chromosome

No significance of derivative chromosome 9 deletion on the clearance kinetics of BCR/ABL fusion transcripts, cytogenetic or molecular response, loss of response, or treatment failure to imatinib mesylate therapy for chronic myeloid leukemia

✍ Dong Hwan (Dennis) Kim; Gizelle Popradi; Lakshmi Sriharsha; Suzanne Kamel-Reid; 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB